Kits containing DLL3 antibody drug conjugates

Patent metadata

Field	Value
Publication number	US-9861708-B2
Application number	US-201715616192-A
Country	US
Kind code	B2
Filing date	Jun 7, 2017
Priority date	Feb 24, 2012
Publication date	Jan 9, 2018
Grant date	Jan 9, 2018

Abstract

Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.

First claim

The invention claimed is:

1. A kit for treating cancer comprising:
(a) one or more containers containing a composition comprising an antibody drug conjugate, or a pharmaceutically acceptable salt thereof, comprising a humanized anti-DLL3 antibody conjugated or associated with one or more cytotoxic agents, wherein the anti-DLL3 antibody comprises a light chain variable region set forth as SEQ ID NO: 212 and a heavy chain variable region set forth as SEQ ID NO: 213;
and wherein the cytotoxic agent comprises a pyrrolobenzodiazepine (PBD) comprising the formula AC:

wherein:
the dotted lines indicate the optional presence of a double bond, and wherein only one of the dotted lines in a given ring can be a double bond;
R 2 is selected from H, OH, ═O, ═CH 2 , CN, R, OR, ═CH—R D , ═C(R D ) 2 , O SO 2 R, CO 2 R, COR, and halo, where R D is selected from R, CO 2 R, COR, CHO, CO 2 H, and halo;
R 6 and R 9 are each independently selected from H, R, OH, OR, SH, SR, NH 2 , NHR, NRR′, NO 2 , Me 3 Sn and halo;
R 7 is selected from H, R, OH, OR, SH, SR, NH 2 , NHR, NRR′, NO 2 , Me 3 Sn and halo;
R 10 is a linker L connected to the anti-DLL3 antibody;
Q is selected from O, S and NH;
R 11 is either H, or R or, where Q is O, SO 3 M, where M is a metal cation;
R and R′ are each independently selected from optionally substituted C 1-12 alkyl, C 3-20 heterocyclyl and C 5-20 aryl groups, and optionally in relation to the group NRR′, R and R′ together with the nitrogen atom to which they are attached form an optionally substituted 4-, 5-, 6- or 7-membered heterocyclic ring;
X is selected from O, S, and N(H);
R 2″ , R 6″ , R 7″ , R 9″ , and X″ are as defined according to R 2 , R 6 , R 7 , R 9 , and X, respectively; and
R″ is a C 3-12 alkylene group, which comprises a chain optionally interrupted by one or more heteroatoms, one or more rings, or both one or more heteroatoms and one or more rings, wherein the optional one or more rings are optionally substituted; and
(b) a label or package insert on or associated with the one or more containers indicating the composition is for treating cancer.

2. The kit of claim 1 , wherein the one or more containers is an intravenous solution bag, a vial, a bottle, or a syringe.

3. The kit of claim 1 , wherein the composition is provided as a lyophilized powder.

4. The kit of claim 3 , wherein the label or package insert indicate reconstitution of the lyophilized powder in sterile water or buffered saline.

5. The kit of claim 4 , wherein the label or package insert further indicate addition of one or more substances to inhibit protein aggregation.

6. The kit of claim 5 , wherein the one or more substances to inhibit protein aggregation is sucrose.

7. The kit of claim 1 , wherein the label or package insert indicate that the composition is for treating lung cancer.

8. The kit of claim 7 , wherein the label or package insert indicate that the composition is for treating small cell lung cancer.

9. The kit of claim 1 , wherein the label or package insert indicate that the composition is for treating large cell neuroendocrine carcinoma.

10. The kit of claim 1 , wherein the label or package insert indicate that the composition is for treating thyroid cancer.

11. The kit of claim 1 , wherein the label or package insert indicate that that composition is for treating prostate cancer.

12. The kit of claim 1 , wherein the antibody drug conjugate comprises the structure:

wherein:
CBA is a cell binding agent, which is the humanized anti-DLL3 antibody;
A, L 1 , and L 2 are components of the linker L;
A is a connecting group connecting L 1 to the cell binding agent (CBA);
L 1 is optionally a cleavable linker;
L 2 is a covalent bond or together with the —OC(═O)— group forms a self-immolative linker; and
wherein the linker L is attached to the pyrrolobenzodiazepine (PBD) at the position of the asterisk (*).

13. The kit of claim 12 , wherein L 1 comprises a cleavable linker.

14. The kit of claim 13 , wherein the cleavable linker comprises a dipeptide.

15. The kit of claim 14 , wherein the dipeptide is Phe-Lys, Val-Ala, Val-Lys, Ala-Lys, Val-Cit, Phe-Cit, Leu-Cit, Ile-Cit, Phe-Arg, or Trp-Cit.

16. The kit of claim 15 , wherein the dipeptide is Val-Ala.

17. The kit of claim 12 , wherein the moiety:

comprises the structure:

wherein the wavy line indicates the point of attachment of the structure directly to A or to a remaining portion of L 1 that is further connected to A.

18. The kit of claim 1 , wherein R 2 is R, wherein R is a C 5-20 aryl group.

19. The kit of claim 1 , wherein R 6 and R 9 are H.

20. The kit of claim 1 , wherein R 7 is OR.

21. The kit of claim 20 , wherein R is a C 1 alkyl.

22. The kit of claim 1 , wherein Q is O.

23. The kit of claim 22 , wherein R 11 is H.

24. The kit of claim 1 , wherein X and X″ are O.

25. The kit of claim 1 , wherein the antibody is conjugated to the one or more cytotoxic agents.

26. A kit for treating cancer comprising:
(a) one or more containers containing a composition comprising an antibody drug conjugate, or a pharmaceutically acceptable salt thereof, comprising a humanized anti-DLL3 antibody conjugated to one or more cytotoxic agents, wherein the anti-DLL3 antibody comprises a light chain variable region set forth as SEQ ID NO: 212 and a heavy chain variable region set forth as SEQ ID NO: 213;
wherein the cytotoxic agent comprises a pyrrolobenzodiazepine (PBD) comprising the formula AC:

wherein:
the dotted lines indicate the optional presence of a double bond, and wherein only one of the dotted lines in a given ring can be a double bond;
R 2 is selected from H, OH, ═O, ═CH 2 , CN, R, OR, ═CH—R D , ═C(R D ) 2 , O SO 2 R, CO 2 R, COR, and halo, where R D is selected from R, CO 2 R, COR, CHO, CO 2 H, and halo;
R 6 and R 9 are each independently selected from H, R, OH, OR, SH, SR, NH 2 , NHR, NRR′, NO 2 , Me 3 Sn and halo;
R 7 is selected from H, R, OH, OR, SH, SR, NH 2 , NHR, NRR′, NO 2 , Me 3 Sn and halo;
R 10 is a linker L connected to the anti-DLL3 antibody;
Q is selected from O, S and NH;
R 11 is either H, or R or, where Q is O, SO 3 M, where M is a metal cation;
R and R′ are each independently selected from optionally substituted C 1-2 alkyl, C 3-20 heterocyclyl and C 5-20 aryl groups, and optionally in relation to the group NRR′, R and R′ together with the nitrogen atom to which they are attached form an optionally substituted 4-, 5-, 6- or 7-membered heterocyclic ring;
X is selected from O, S, and N(H);
R 2″ , R 6″ , R 7″ , R 9″ , and X″ are as defined according to R 2 , R 6 , R 7 , R 9 , and X, respectively; and

Assignees

• Abbvie Stemcentrx Llc

Inventors

• Stull Robert A
• Saunders Laura
• Dylla Scott J
• Foord Orit
• Liu David
• Torgov Michael
• Shao Hui

Classifications

• A61P35/00

  Antineoplastic agents · CPC title

• A61P11/00

  Drugs for disorders of the respiratory system · CPC title

• G01N33/5759

  involving compounds localised on the membrane of tumour or cancer cells · CPC title

• G01N33/5752

  of the lungs · CPC title

• C07K2317/56

  variable (Fv) region, i.e. VH and/or VL · CPC title